An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation

From BugSigDB
Reviewed Marked as Reviewed by Atrayees on 2023-6-28
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
Authors
Chen W, Bi Z, Zhu Q, Gao H, Fan Y, Zhang C, Liu X, Ye M
Journal
American journal of translational research
Year
2021
Keywords:
16S rRNA sequencing, Parkinson’s disease (PD), constipation, gut microbiota
Parkinson's disease (PD) is a degenerative disease of the central nervous system (CNS) and is common among the middle-aged and elderly populations. Increasing evidence shows that the gut microbiota may trigger PD through the "gut-microbiota-brain" axis. A previous study revealed that constipation, one of the non-motor symptoms of PD, affects gut microbiota and the progression of PD. However, whether constipation is involved in gut microbiota-associated PD is largely unknown. Therefore, we investigated the relationship between gut microbiota, PD, and constipation in this study. We carried out 16S rRNA sequencing in 15 constipated PD patients (C-PD), 14 non-constipated PD (NC-PD) patients, and 15 healthy controls to evaluate the microbial population. Furthermore, co-occurrence networks were used to assess the gut ecology of the three groups. Spearman analyses were used to analyze the correlation between the differential microbiota and the clinical features. The results showed that there were differences in the composition of the gut microbiota among the C-PD group, the NC-PD group, and the healthy controls. No significant differences were observed in the alpha diversity among the three groups, but the beta diversity differed significantly among the groups. Compared with the healthy controls, the abundance of Hungatella and Collinsella was increased and the abundance of Lachnospira and Fusicatenibacter was reduced in the PD patients' feces. Compared with the NC-PD group, the relative abundance of Megamonas and Holdemanella were lower, while Hungatella, Streptococcus and Anaerotruncus were enriched in the C-PD group. The co-occurrence network analysis showed that the C-PD group presented a different microbial community relationship compared with the NC-PD group and the healthy controls. Our study provides strong evidence that the gut microbiota may be related to constipation in PD. In addition, our data suggest an association between the differential microbiota genera and the clinical features of PD. Therefore, modulating gut microbiota may be another way to monitor and optimize PD treatment.

Experiment 1


Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin, Peace Sandy

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Parkinson's disease IDIOPATHIC PARKINSON DIS,Idiopathic Parkinson Disease,Idiopathic Parkinson's Disease,IDIOPATHIC PARKINSONS DIS,Idiopathic PD,LEWY BODY PARKINSON DIS,Lewy Body Parkinson Disease,Lewy Body Parkinson's Disease,Paralysis agitans,paralysis agitans,PARKINSON DIS,PARKINSON DIS IDIOPATHIC,Parkinson disease,Parkinson Disease, Idiopathic,Parkinson syndrome,Parkinson's,Parkinson's disease,Parkinson's disease (disorder),Parkinson's disease NOS,Parkinson's disease NOS (disorder),Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinson's syndrome,Parkinsonian disorder,Parkinsonism, Primary,Parkinsons,PARKINSONS DIS,PARKINSONS DIS IDIOPATHIC,PARKINSONS DIS LEWY BODY,Parkinsons disease,Primary Parkinsonism,parkinson's disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy Controls and Parkinson's Disease patients with constipation
Group 1 name Corresponds to the case (exposed) group for case-control studies
Parkinson's Disease patients without constipation
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
The PD patients were all screened from the outpatients and inpatients in the Department of Neurology and their Wexner scores (evaluation of constipation severity) were collected. Patients diagnosed with idiopathic PD by a neurologist according to the revised PD diagnostic criteria published by the International Movement Disorders Association in 2015.
Group 0 sample size Number of subjects in the control (unexposed) group
30
Group 1 sample size Number of subjects in the case (exposed) group
14
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months.

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4-V5
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2

Alpha Diversity

Chao1 Abundance-based estimator of species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Source: Figure 1G

Description: Difference contribution analysis chart

Abundance in Group 1: increased abundance in Parkinson's Disease patients without constipation

NCBI Quality ControlLinks
Sutterella parvirubra
uncultured Kopriimonas sp.

Revision editor(s): Jacquelynshevin

Experiment 2


Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy Controls
Group 1 name Corresponds to the case (exposed) group for case-control studies
Parkinson's Disease patients without constipation and Parkinson's Disease patients with constipation
Group 0 sample size Number of subjects in the control (unexposed) group
15
Group 1 sample size Number of subjects in the case (exposed) group
29

Lab analysis

Statistical Analysis

Alpha Diversity

Chao1 Abundance-based estimator of species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Source: Figure 1G

Description: Difference contribution analysis chart

Abundance in Group 1: decreased abundance in Parkinson's Disease patients without constipation and Parkinson's Disease patients with constipation

NCBI Quality ControlLinks
Phocaeicola massiliensis
Lachnospira
Fusicatenibacter

Revision editor(s): Jacquelynshevin

Experiment 3


Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy Controls and Parkinson's Disease patients without constipation
Group 1 name Corresponds to the case (exposed) group for case-control studies
Parkinson's Disease patients with constipation
Group 0 sample size Number of subjects in the control (unexposed) group
29
Group 1 sample size Number of subjects in the case (exposed) group
15

Lab analysis

Statistical Analysis

Alpha Diversity

Chao1 Abundance-based estimator of species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Atrayees on 2023-6-28

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Source: Figure 1G

Description: Difference contribution analysis chart

Abundance in Group 1: increased abundance in Parkinson's Disease patients with constipation

NCBI Quality ControlLinks
Actinomycetota
Oscillospiraceae bacterium
Subdoligranulum sp. 4_3_54A2FAA
Coriobacteriia
Coriobacteriales
Coriobacteriaceae
Collinsella
Hungatella
Lactobacillales
Bacilli
Streptococcaceae

Revision editor(s): Jacquelynshevin

Experiment 4


Reviewed Marked as Reviewed by Atrayees on 2023-6-27

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Parkinson's Disease patients without constipation
Group 0 sample size Number of subjects in the control (unexposed) group
14

Lab analysis

Statistical Analysis

Alpha Diversity

Chao1 Abundance-based estimator of species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Atrayees on 2023-6-27

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Source: Figure 2H

Description: Difference contribution analysis chart.

Abundance in Group 1: decreased abundance in Parkinson's Disease patients with constipation

NCBI Quality ControlLinks
Holdemanella
Megamonas
Leyella stercorea
Rhodospirillaceae
Rhodospirillales

Revision editor(s): Jacquelynshevin

Signature 2

Reviewed Marked as Reviewed by Atrayees on 2023-6-27

Curated date: 2023/05/21

Curator: Jacquelynshevin

Revision editor(s): Jacquelynshevin

Source: Figure 2H

Description: Difference contribution analysis chart.

Abundance in Group 1: increased abundance in Parkinson's Disease patients with constipation

NCBI Quality ControlLinks
Anaerotruncus
Bacilli
Hungatella
Lactobacillales
Oscillospiraceae bacterium
Streptococcaceae
Streptococcus
Subdoligranulum sp. 4_3_54A2FAA
Streptococcus salivarius

Revision editor(s): Jacquelynshevin